Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alcon Research
Each subject's expected participation in the study is up to 37.5 months which includes up to 42 days between the screening and surgery visits, and 36 months of post-surgery follow-up. Only one eye per subject will be implanted.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to understand the requirements of the study and willing to follow study instructions, provide written informed consent, and agree to comply with all study requirements, including the required study follow-up visits
Diagnosis of primary open angle glaucoma (POAG)
Medicated intraocular pressure (IOP) of ≥10 millimeters mercury (mmHg) and ≤25 mmHg, or an unmedicated IOP of ≥21 mmHg and ≤33 mmHg
An operable age-related cataract eligible for phacoemulsification
Visual acuity as specified in the protocol
You may not be if
Inability to complete a visual field test prior to surgery
Use of ocular hypotensive medication/s, as specified in the protocol
Diagnosis of glaucoma other than POAG, as specified in the protocol
Other medical conditions, as specified in the protocol
Proliferative diabetic retinopathy
Previous surgery for retinal detachment
Previous corneal surgery
Wet age-related macular degeneration
Poor vision in the non-study eye not due to cataract
Significant ocular inflammation or infection within 30 days of screening visit
Uncontrolled systemic diseases that may put the subject's health at risk and/or prevent the subject from completing all study visits
Women who are pregnant or nursing
Clareo Health | Post Approval Study of the CyPass System
